John H. Strickler
Duke University · 434 works · 9,700 citations · h-index 39
Top works
- KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
- Hepatic portal arteriovenous fistula; a case report.
- Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study
- Treatment of Metastatic Colorectal Cancer: ASCO Guideline
- Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline
- Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer
- Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma
- Direct preconditioning of cultured chick ventricular myocytes. Novel functions of cardiac adenosine A2a and A3 receptors.
- ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
- Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer
- Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
- Parenteral nutrition; pre- and postoperative use of glucose, amino acids and alcohol; a preliminary study.
- Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge
- Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study
- 1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
- 551O Impact of baseline molecular alterations on the efficacy of tucatinib (TUC) plus trastuzumab (Tras) for HER2+, RAS WT metastatic CRC (mCRC) in MOUNTAINEER
- Desmosome frequency: Experimental alteration may correlate with differential cell adhesion
- Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
- First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors
- Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): Initial results from the MOUNTAINEER trial